Day: July 8, 2024

NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the European Commission, based on a positive opinion issued by the European Medicines Agency (EMA), has granted Orphan Drug Designation (ODD) for SLS009, a novel, and highly selective CDK9 inhibitor, for the treatment of acute myeloid leukemia (AML). “We are thrilled to receive ODD from the EMA for the treatment of AML. This designation along with the recently announced strong preliminary Phase 2 data and previous FDA ODD designation reinforces our continued progress and commitment to developing SLS009 as a potential treatment for AML,” said Angelos Stergiou,...

Extensive Issued and Pending IP Patent Applications Acquired with License Agreement SARASOTA, FL, July 08, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into an exclusive, global license agreement with Columbia University to further develop, manufacture, and commercialize its lead drug candidate, SPC-15, an intranasal treatment for stress-induced affective disorders and PTSD. Silo recently submitted a pre-IND briefing package and meeting request for SPC-15 to the U.S. Food and Drug Administration (FDA) earlier this month. The Company is currently engaged in the final steps required before...

On 4 March 2024, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 13 of 1 March 2024. Under the programme, Schouw & Co. will acquire shares for up to DKK 200 million during the period 4 March 2024 to 31 December 2024. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).Trading day No. of shares Average price Amount    Accumulated until 28/6/2024 140,500 543.47 76,357,900    Monday, 1 July 2024 1,900 550.28 1,045,532    Tuesday, 2 July 2024 1,800 554.46 998,028    Wednesday, 3 July 2024 1,700 559.47 951,099    Thursday, 4 July 2024 1,600 564.84 903,744    Friday,...

Publication of data relating to RenovoRx’s targeted therapy platform to treatment of Locally Advanced Pancreatic Cancer (LAPC) is expected to be in the Summer 2024 issue of a prestigious journal LOS ALTOS, Calif., July 08, 2024 (GLOBE NEWSWIRE) — RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced acceptance for publication in an international peer-reviewed journal, The Oncologist. The manuscript is titled, “Treatment of Locally Advanced Pancreatic Cancer (LAPC) Using Localized Trans-Arterial Micro Perfusion (TAMP™) of Gemcitabine: Combined Analysis of RR1 and RR2” and expected in the Summer 2024 issue of The Oncologist The manuscript’s lead author is Hassan Hatoum, MD,...

3D Systems’ DMP Flex 350 Dual3D Systems’ DMP Flex 350 platform is designed for flexible application use from application development to serial production.Collaboration intended to catalyze metal AM applications in high-criticality markets Precision Resource integrating two 3D Systems DMP Flex 350 Dual printers into manufacturing workflow to support efforts DMP Flex 350’s best-in-class environmental control, inert atmosphere ensures exceptionally high-quality parts for precision applicationsROCK HILL, S.C. and SHELTON, Conn., July 08, 2024 (GLOBE NEWSWIRE) — Today, 3D Systems (NYSE:DDD), a leading additive manufacturing solutions provider, and Precision Resource, a leader in the production of critical components for the automotive, heavy-duty, aerospace, and medical device industries, announced they have entered...

On 22 March 2024, Pro Kapital entered into a share purchase agreement to acquire a 67.5% stake in Preatoni Nuda Proprieta S.R.L. (registered in Milan, Italy). Pursuant to the terms and conditions of the senior secured callable fixed rate bonds 2020/2028 with ISIN SE0013801172, with a total nominal amount outstanding of EUR 19,950,000, issued by Pro Kapital, Pro Kapital is obliged to pledge all of Pro Kapital’s shares of the acquired company in favour of the agent Nordic Trustee & Agency AB and all the bondholders (represented by Nordic Trustee & Agency AB) after the completion of the above mentioned share purchase. Pro Kapital announces that it has entered into the required notarial deed of pledge in Italy on 5 July 2024 in respect of 67.5% of the shares in Preatoni Nuda Proprieta S.R.L. and the Italian notary submitted the relevant...